In a post on the social‑media platform X, Timpson’s James Timpson noted that the chain’s shops across the United Kingdom have been "doing" a sharp rise in free belt‑hole adjustments for customers who have lost weight on the new injectable drugs.
The 680% surge, according to Timpson, reflects a broader shift in consumer health: recent estimates suggest that roughly 2.4 million people in the UK are currently prescribed weight‑loss medications like Ozempic and Mounjaro.
Timpson, which offers complimentary belt‑hole services in its stores, says the demand for smaller‑size belts is directly linked to the rapid weight loss reported by users of these drugs, prompting more shoppers to seek a better fit for their clothing.
The company’s observation adds a tangible, everyday illustration of how the growing use of GLP‑1 agonist injections is affecting not just health statistics but also routine retail services.